Robin Wiltshire

1.1k total citations · 1 hit paper
17 papers, 824 citations indexed

About

Robin Wiltshire is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Robin Wiltshire has authored 17 papers receiving a total of 824 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pulmonary and Respiratory Medicine, 13 papers in Oncology and 5 papers in Cancer Research. Recurrent topics in Robin Wiltshire's work include Lung Cancer Treatments and Mutations (11 papers), Lung Cancer Research Studies (8 papers) and Lung Cancer Diagnosis and Treatment (6 papers). Robin Wiltshire is often cited by papers focused on Lung Cancer Treatments and Mutations (11 papers), Lung Cancer Research Studies (8 papers) and Lung Cancer Diagnosis and Treatment (6 papers). Robin Wiltshire collaborates with scholars based in United States, United Kingdom and Japan. Robin Wiltshire's co-authors include D. Ross Camidge, Alice T. Shaw, Benjamin Solomon, Keith D. Wilner, Caicun Zhou, Sai‐Hong Ignatius Ou, S. Martin Shreeve, Patrick Schnell, Myung‐Ju Ahn and Lucio Crinò and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

Robin Wiltshire

17 papers receiving 814 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non–Small-Cell Lung Cancer and Brain Metastases

2015 468 citations Daniel B. Costa, Alice T. Shaw et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robin Wiltshire United States	11	721	556	290	150	50	17	824
Stéphanie Deudon Switzerland	5	495 0.7×	481 0.9×	356 1.2×	177 1.2×	20 0.4×	10	786
Ines Deleu Belgium	10	508 0.7×	695 1.3×	347 1.2×	264 1.8×	67 1.3×	15	957
Lisa Cupit United States	9	647 0.9×	462 0.8×	404 1.4×	217 1.4×	31 0.6×	15	891
Anna Maria Calella Italy	5	658 0.9×	541 1.0×	195 0.7×	186 1.2×	49 1.0×	9	774
Karin Holmskov Hansen Denmark	13	801 1.1×	622 1.1×	233 0.8×	160 1.1×	78 1.6×	34	945
Anna Wrona Poland	12	519 0.7×	449 0.8×	180 0.6×	96 0.6×	53 1.1×	34	692
Lilia Stelmakh Russia	4	1.1k 1.5×	935 1.7×	226 0.8×	159 1.1×	20 0.4×	8	1.2k
Sandhya Srinivas United States	9	396 0.5×	479 0.9×	250 0.9×	199 1.3×	24 0.5×	18	748
Vlatka Smoljanović Switzerland	8	499 0.7×	400 0.7×	121 0.4×	147 1.0×	25 0.5×	19	566
Martin Olivo United States	15	475 0.7×	1.0k 1.8×	265 0.9×	270 1.8×	87 1.7×	38	1.2k

Countries citing papers authored by Robin Wiltshire

Since Specialization

Citations

This map shows the geographic impact of Robin Wiltshire's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robin Wiltshire with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robin Wiltshire more than expected).

Fields of papers citing papers by Robin Wiltshire

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robin Wiltshire. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robin Wiltshire. The network helps show where Robin Wiltshire may publish in the future.

Co-authorship network of co-authors of Robin Wiltshire

This figure shows the co-authorship network connecting the top 25 collaborators of Robin Wiltshire. A scholar is included among the top collaborators of Robin Wiltshire based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robin Wiltshire. Robin Wiltshire is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Nogami, Naoyuki, et al.. (2023). Effectiveness of Crizotinib in Patients with ROS1 -Positive Non-Small-Cell Lung Cancer: Real-World Evidence in Japan. Future Oncology. 19(37). 2453–2463. 2 indexed citations

Goto, Yasushi, Takehito Shukuya, Hironori Kikkawa, et al.. (2023). Real‐world therapeutic effectiveness of lorlatinib after alectinib in Japanese patients with ALK‐positive non‐small‐cell lung cancer. Cancer Science. 114(6). 2560–2568. 10 indexed citations

Tremblay, Gabriel, Laura Iadeluca, Patrick Daniele, et al.. (2022). Effectiveness of crizotinib versus entrectinib in ROS1 -positive non-small-cell lung cancer using clinical and real-world data. Future Oncology. 18(17). 2063–2074. 14 indexed citations

Felip, Enriqueta, Alice T. Shaw, Alessandra Bearz, et al.. (2021). Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs. Annals of Oncology. 32(5). 620–630. 68 indexed citations

Ou, Sai‐Hong Ignatius, Benjamin Solomon, Alice T. Shaw, et al.. (2020). 1302P Lorlatinib in patients with ALK+ NSCLC treated beyond initial disease progression. Annals of Oncology. 31. S842–S842. 1 indexed citations

Goto, Yasushi, Nobuyuki Yamamoto, Elizabeth T. Masters, et al.. (2020). Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study. Advances in Therapy. 37(7). 3311–3323. 13 indexed citations

Copley‐Merriman, Catherine, James A. Kaye, Marc Chioda, et al.. (2019). <p>Systematic review of sequencing of ALK inhibitors in <em>ALK</em>-positive non-small-cell lung cancer</p>. PubMed. Volume 10. 11–20. 16 indexed citations

Camidge, D. Ross, Benjamin Solomon, Enriqueta Felip, et al.. (2019). Intracranial and extracranial efficacy of lorlatinib in the post second-generation ALK tyrosine kinase inhibitor (TKI) setting. Annals of Oncology. 30. v608–v609. 1 indexed citations

Copley‐Merriman, Catherine, et al.. (2018). Systematic Literature Review (SLR) Of Sequencing Of Anaplastic Lymphoma Kinase (ALK) Inhibitors In ALK-Positive Non-Small Cell Lung Cancer (NSCLC). Value in Health. 21. S49–S50. 1 indexed citations

10.

Goto, Yasushi, Nobuyuki Yamamoto, Elizabeth T. Masters, et al.. (2018). P3.01-30 Treatment Sequencing in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC) in Japan. Journal of Thoracic Oncology. 13(10). S878–S879. 1 indexed citations

11.

Costa, Daniel B., Alice T. Shaw, Sai‐Hong Ignatius Ou, et al.. (2015). Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non–Small-Cell Lung Cancer and Brain Metastases. Journal of Clinical Oncology. 33(17). 1881–1888. 468 indexed citations breakdown →

12.

Donskov, Frede, M. Dror Michaelson, Igor Puzanov, et al.. (2015). Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients. British Journal of Cancer. 113(11). 1571–1580. 76 indexed citations

13.

Wit, Djoeke de, Nielka P. van Erp, Reza Khosravan, et al.. (2014). Effect of gastrointestinal resection on sunitinib exposure in patients with GIST. BMC Cancer. 14(1). 575–575. 13 indexed citations

14.

Molina, Ana M., Xun Lin, Beata Korytowsky, et al.. (2013). Sunitinib objective response in metastatic renal cell carcinoma: Analysis of 1059 patients treated on clinical trials. European Journal of Cancer. 50(2). 351–358. 111 indexed citations

15.

Donskov, Frede, M. Dror Michaelson, Igor Puzanov, et al.. (2012). Comparative Assessment of Sunitinib-Associated Adverse Events (AES) as Potential Biomarkers of Efficacy in Metastatic Renal Cell Carcinoma (MRCC). Annals of Oncology. 23. ix259–ix259. 11 indexed citations

16.

Molina, Ana M., Jingbo Zhang, Xun Lin, et al.. (2012). Sunitinib objective response (OR) in metastatic renal cell carcinoma (mRCC): Analysis of 1,059 patients treated on clinical trials.. Journal of Clinical Oncology. 30(15_suppl). 4542–4542. 5 indexed citations

17.

Khosravan, Reza, Xin Huang, Robin Wiltshire, Mariajosé Lechuga, & Robert J. Motzer. (2012). A retrospective analysis of data from two trials of sunitinib in patients with advanced renal cell carcinoma (RCC): Pitfalls of efficacy subgroup analyses based on dose-reduction status.. Journal of Clinical Oncology. 30(5_suppl). 363–363. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact